Xencor (Xencor) Dividend Payout Ratio : 0.00 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Xencor Dividend Payout Ratio?

Xencor's dividend payout ratio for the months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for Xencor's Dividend Payout Ratio or its related term are showing as below:

XNCR's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.415
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-05-01), the Dividend Yield % of Xencor is 0.00%.

Xencor's Dividends per Share for the months ended in Dec. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Xencor Dividend Payout Ratio Historical Data

The historical data trend for Xencor's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xencor Dividend Payout Ratio Chart

Xencor Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividend Payout Ratio

Get a 7-Day Free Trial

Xencor Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Xencor's Dividend Payout Ratio

For the Biotechnology subindustry, Xencor's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xencor's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xencor's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Xencor's Dividend Payout Ratio falls into.

Xencor Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Xencor's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	EPS without NRI (A: Dec. 2023 )
	=	0	/	-2.075
	=	N/A

Xencor's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-0.482
	=	N/A

Xencor (NAS:XNCR) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Xencor Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Xencor's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Xencor (Xencor) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xencor Inc (NAS:XNCR) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

XE9:Germany

Address

111 West Lemon Avenue, Monrovia, CA, USA, 91016

Website

http://www.xencor.com

Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.

Executives

Bassil I Dahiyat	director, officer: PRESIDENT & CEO	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Barbara Klencke	director	C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Allen Yang	officer: SR. VICE PRESIDENT & CMO	C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Celia Eckert	officer: VP, GENERAL COUNSEL	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
John R Desjarlais	officer: SR. VICE PRESIDENT & CSO	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
John J Kuch	officer: SR. VICE PRESIDENT & CFO	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Nancy Valente	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Richard J Ranieri	director	3005 FIRST AVE, SEATTLE WA 98121
Ellen Feigal	director	C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Yujiro S Hata	director	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Dagmar Rosa-bjorkeson	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Alan Bruce Montgomery	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Kevin Charles Gorman	director	12790 EL CAMINO REAL, SAN DIEGO CA 92130
Kurt A Gustafson	director	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Stafford John S Iii	10 percent owner	230 SOUTH LASALLE STREET 400, CHICAGO IL 60604